EUCTR2014-001670-34-ES进行中（未招募）1 期
A Phase IIa, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and effects of AZP-531, an Unacylated Ghrelin analog, on food-related behavior in patients with Prader-Willi Syndrome
Alize Pharma0 个研究点目标入组 40 人开始时间: 2014年10月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male and female patients with genetically confirmed diagnosis of Prader-Willi Syndrome using standard DNA methylation test or fluorescent in situ hybridization
- •-Patients aged 18 years to 40 years old inclusive initially
- •o Patients aged 12 years old to less than 18 years old after formal decision of the Data Monitoring Committee
- •-Have evidence of increased appetite or hyperphagia, as judged by the investigator
- •-Patients on well-balanced controlled diet and on a regular exercise program as recommended in common clinical practice for this patient population
- •-Women of Child Bearing Potential (WCBP) must have a negative pregnancy test on admission to the study center
- •-All WCBP, sexually active male subjects, and all partners of subjects should agree to use adequate methods of birth control (diaphragm, condoms with spermicide?) throughout the study and for 30 days after the last dose of study drug
- •-Adequate renal function, defined as serum creatinine inferior or equal to 1.5 x Upper Limit of Normal (ULN) and urine protein/creatinine ratio <0.2
- •-Adequate hepatic function, defined as total bilirubin inferior or equal to 1.5 x ULN and Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) levels inferior or equal to 3 x ULN
- •-Growth hormone treatment will be permitted if doses have been stable for at least 1 month prior to screening
- •-Psychotropic treatment will be permitted and should be stable at least 1 month prior to screening
- •-Any other treatment including thyroid hormones should be stable for at least 1 month prior to screening
- •-Informed consent signed by the patient, parent or legal guardian, as appropriate
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-History of chronic liver disease, such as cirrhosis or chronic hepatitis due to any cause, or suspected alcohol abuse
- •- History of acute or chronic pancreatitis
- •-Type 1 diabetes
- •-Insulin treatment
- •-Use of weight loss agents or drugs known to affect appetite (including GLP-1 analogs) within 2 months prior to screening
- •-Co-morbid condition or disease (such as respiratory disease or psychiatric disorder) diagnosed less than 1 month prior to screening
- •-Co-morbid condition or disease or abnormal laboratory finding that would in the investigator judgment increase the subject risk to participating in this study and that will not allow the patient to complete the study
- •-History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs
- •-Participation in a clinical trial with an investigational agent within 2 months prior to screening
- •-Clinically significant abnormalities on ECG at screening
- •-Pregnant or lactating woman
- •-History of hypersensitivity to drugs with a similar chemical structure or class as AZP-531 (Acylated Ghrelin and Unacylated Ghrelin)
- •-Unwillingness or inability to follow the procedures outlined in the protocol
研究者
相似试验
进行中（未招募）
1 期
GLPG2737 on top of Orkambi in subjects with cystic fibrosisCystic fibrosisEUCTR2017-002181-42-DEGalapagos NV18
进行中（未招募）
1 期
A study to evaluate how safe MVA.HTI and ChAdOx1.HTI vaccines with vesatolimod are in participants with early treated HIV-1 infection.Human immunodeficiency virus type 1MedDRA version: 20.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-002125-30-ESAELIX Therapeutics50
进行中（未招募）
1 期
A study looking at the safety, tolerability and efficacy of the study drug GLPG2222 in patients with cystic fibrosis who have the F508del CFTR mutation on both allelesMedDRA version: 19.1Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2016-004477-40-NLGalapagos NV50
进行中（未招募）
不适用
A Phase IIa study to evaluate the safety, tolerability, and effects of AZP-531 on food-related behavior in patients with Prader-Willi SyndromePrader-Willi SyndromeMedDRA version: 18.0Level: HLGTClassification code 10003018Term: Appetite and general nutritional disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 18.0Level: PTClassification code 10036476Term: Prader-Willi syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 18.0Level: HLTClassification code 10003022Term: Appetite disordersSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-001670-34-ITAlize Pharma40
进行中（未招募）
不适用
A Phase IIa, randomized, double-blind, placebo-controlled, exploratory, dose-ranging study to evaluate the safety, effectiveness and pharmacokinetics of three courses of DC-TAB treatment in patients with multiple sclerosisRelapsing multiple sclerosisMedDRA version: 14.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-004475-36-BGDelta Crystallon B.V.